Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CGTX
STRONG SELLCognition Therapeutics, Inc. · Healthcare · United States · $82M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. Its proprietary discovery platform has identified candidates like elayta (CT1812), which targets the sigma-2 receptor complex to protect synapses from toxic oligomers. The company occupies a specialized niche in neurodegenerative research, focusing on disease-modifying mechanisms for Alzheimer's and dry AMD.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.29 | -0.31 | -0.86 | -0.32 | — | -0.23 | -0.32 | -0.28 | — |
| Shares | 89.5M | 89.5M | 59.9M | 88.9M | -0.7% | 89.5M | — | — | — |
| Debt | 1.5M | 1.2M | 0.8M | 0.6M | -24.4% | 0.5M | — | — | — |
| Equity | 40.2M | 24.5M | 18.8M | 34.3M | -5.2% | — | — | — | — |
| Op CF | -18.5M | -16.0M | -28.5M | -24.6M | — | -20.3M | — | — | — |
| Inv CF | -0.2M | -0.1M | -4.0K | 9.0K | — | — | — | — | — |
| Fin CF | 5.5M | 4.5M | 23.6M | 36.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CGTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CGTX | Cognition Therapeutics, Inc.(you) | $82M | 7 | STRONG SELL |
| HRTX | Heron Therapeutics, Inc. | $86M | 8 | STRONG SELL |
| GANX | Gain Therapeutics, Inc. | $75M | 8 | STRONG SELL |
| KLRS | Kalaris Therapeutics, Inc. | $89M | 9 | STRONG SELL |
| ANVS | Annovis Bio, Inc. | $71M | 8 | STRONG SELL |
| TELO | Telomir Pharmaceuticals, Inc. | $79M | 11 | STRONG SELL |
| BMEA | Biomea Fusion, Inc. | $90M | 10 | STRONG SELL |
| IBIO | iBio, Inc. | $71M | 9 | STRONG SELL |
| GOSS | Gossamer Bio, Inc. | $66M | 8 | STRONG SELL |
| ALDX | Aldeyra Therapeutics, Inc. | $92M | 4 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%